エキソソーム研究関連製品の世界市場予測（～2024年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 MARKET SCOPE 15
1.3.1 MARKET COVERED 15
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 16
1.5 LIMITATIONS 16
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.1.1 SECONDARY DATA 19
2.1.1.1 Key data from secondary sources 19
2.1.2 PRIMARY DATA 20
2.1.2.1 Key data from primary sources 20
2.2 MARKET SIZE ESTIMATION 21
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.4 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 29
4.1 EXOSOMES MARKET: OVERVIEW 29
4.2 EXOSOMES MARKET, BY APPLICATION, 2019–2024 (USD MILLION) 30
4.3 EXOSOME MARKET SHARE, BY CANCER APPLICATIONS & REGION (2018) 31
4.4 EXOSOME MARKET, BY END USER, 2019 VS. 2024 (USD MILLION) 32
4.5 EXOSOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 32
5 MARKET OVERVIEW 33
5.1 INTRODUCTION 33
5.2 MARKET DYNAMICS 33
5.2.1 DRIVERS 34
5.2.1.1 Increasing funding for life sciences research 34
5.2.1.2 High global prevalence of cancer 34
5.2.1.3 Increasing interest in exosome-based procedures 35
5.2.2 RESTRAINTS 36
5.2.2.1 Lack of skilled professionals 36
 
5.2.3 OPPORTUNITIES 36
5.2.3.1 Untapped emerging markets 36
5.2.3.2 Growing interest in exosome-based therapeutics 37
5.2.3.3 Personalized medicine 37
6 EXOSOMES MARKET, BY PRODUCT & SERVICE 38
6.1 INTRODUCTION 39
6.2 KITS AND REAGENTS 40
6.2.1 KITS AND REAGENTS SEGMENT TO WITNESS THE HIGHEST GROWTH IN THE EXOSOMES MARKET DURING THE FORECAST PERIOD 40
6.3 INSTRUMENTS 41
6.3.1 INCREASE IN THE NUMBER OF DIAGNOSTIC LABORATORIES OFFERING EXOSOME-BASED TESTS TO DRIVE THE ADOPTION OF INSTRUMENTS 41
6.4 SERVICES 42
6.4.1 EXOSOME SERVICES AID ONCOLOGISTS TO DETECT AND MONITOR CANCER BIOMARKERS FROM A SIMPLE BLOOD OR URINE SAMPLE 42
7 EXOSOMES MARKET, BY APPLICATION 43
7.1 INTRODUCTION 44
7.2 CANCER APPLICATIONS 45
7.2.1 LUNG CANCER 46
7.2.1.1 Increasing prevalence of lung cancer and technological advancements in instruments & assays for liquid biopsy to drive market growth 46
7.2.2 BREAST CANCER 47
7.2.2.1 High prevalence of breast cancer and increasing awareness to drive the market for this segment 47
7.2.3 PROSTATE CANCER 48
7.2.3.1 Liquid biopsy helps detect aggressive prostate cancer before surgery—a key factor driving market growth 48
7.2.4 COLORECTAL CANCER 49
7.2.4.1 Increasing research activities and projects based on exosomes to drive the market for this segment 49
7.2.5 OTHER CANCERS 50
7.2.5.1 Rising incidence of cancer and increasing research funding to drive the market for this segment 50
7.3 NON-CANCER APPLICATIONS 51
7.3.1 WIDE RANGE OF NON-CANCER APPLICATIONS TO DRIVE GROWTH IN THE DEMAND FOR EXOSOMES IN THIS APPLICATION SEGMENT 51
 
8 EXOSOMES MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 ACADEMIC & RESEARCH INSTITUTES 55
8.2.1 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS IN THE EXOSOMES MARKET 55
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 56
8.3.1 SIGNIFICANT DEVELOPMENTS IN RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH IN THIS END-USER SEGMENT 56
8.4 HOSPITALS & CLINICAL TESTING LABORATORIES 57
8.4.1 HOSPITALS & CLINICAL TESTING LABORATORIES USE EXOSOMES FOR THE DIAGNOSIS OF CANCER 57
9 EXOSOMES MARKET, BY REGION 58
9.1 INTRODUCTION 59
9.2 NORTH AMERICA 60
9.2.1 US 63
9.2.1.1 High burden of cancer and favorable public and private funding for research activities to drive market growth 63
9.2.2 CANADA 66
9.2.2.1 Availability of research funding & rising incidence of cancer to drive market growth 66
9.3 EUROPE 69
9.3.1 GERMANY 72
9.3.1.1 Presence of a large number of academic research institutes to support market growth 72
9.3.2 UK 74
9.3.2.1 Growth in the life sciences industry to drive the market for exosomes in the UK 74
9.3.3 FRANCE 77
9.3.3.1 Government initiatives to boost R&D activities in the country and high healthcare expenditure are the key factors driving market growth 77
9.3.4 ROE 79
9.4 ASIA 82
9.4.1 CHINA 85
9.4.1.1 Government initiatives to strengthen the biotechnology industry and the high prevalence of cancer are the major factors driving market growth 85
9.4.2 JAPAN 87
9.4.2.1 High prevalence of cancer and increasing healthcare expenditure are the key drivers for the exosomes market in the country 87
9.4.3 REST OF ASIA 89
9.5 REST OF THE WORLD 92
 
10 COMPETITIVE LANDSCAPE 96
10.1 OVERVIEW 96
10.2 MARKET SHARE ANALYSIS 97
10.3 COMPETITIVE SCENARIO 98
10.3.1 PARTNERSHIPS AND AGREEMENTS (2016–2019) 98
10.3.2 PRODUCT LAUNCHES (2016–2019) 99
10.3.3 ACQUISITIONS (2016–2019) 99
10.3.4 EXPANSIONS (2016–2019) 99
10.4 COMPETITIVE LEADERSHIP MAPPING (2017) 100
10.4.1 VANGUARDS 100
10.4.2 INNOVATORS 100
10.4.3 DYNAMIC PLAYERS 100
10.4.4 EMERGING PLAYERS 101
11 COMPANY PROFILES 102
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 BIO-TECHNE 102
11.2 THERMO FISHER SCIENTIFIC INC. 105
11.3 SYSTEM BIOSCIENCES (SBI) 108
11.4 NX PHARMAGEN 109
11.5 QIAGEN N.V. 110
11.6 MILTENYI BIOTECH 113
11.7 AMS BIOTECHNOLOGY LTD. 114
11.8 NANOSOMIX 115
11.9 LONZA GROUP AG 116
11.10 NORGEN BIOTEK CORP. 119

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX 120
12.1 INSIGHTS OF INDUSTRY EXPERTS 120
12.2 DISCUSSION GUIDE 121
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 124
12.4 AVAILABLE CUSTOMIZATIONS 126
12.5 RELATED REPORTS 126
12.6 AUTHOR DETAILS 127